Differential expression levels of plasma-derived miR-146b and miR-155 in papillary thyroid cancer

Oral Oncology

Volumn 51, Issue 1, 2015, Pages 77-83

  Lee, Yoon Se ^a   Lim, Yun Sung ^b   Lee, Jin Choon ^c   Wang, Soo Geun ^c   Park, Hee Young ^c   Kim, Shine Young ^d   Lee, Byung Joo ^c  

^a University of Ulsan College of Medicine   (South Korea)

^b Dongguk University Ilsan Hospital   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

^d Pusan National University   (South Korea)

Author keywords

MicroRNA; Papillary thyroid cancer; Plasma; Tumor size

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 146B; MICRORNA 155; MICRORNA 221; MICRORNA 222; UNCLASSIFIED DRUG; MICRORNAS; MIRN146 MICRORNA, HUMAN; MIRN155 MICRORNA, HUMAN; TUMOR MARKERS, BIOLOGICAL;

ADULT; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PLASMA; SENSITIVITY AND SPECIFICITY; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; BLOOD; GENETICS; HUMANS; REAL-TIME POLYMERASE CHAIN REACTION; THYROID NEOPLASMS;

HUMANS; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84920548464     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2014.10.006     Document Type: Article

References (41)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
2. Cannell IG, Kong YW, Bushell M. How do microRNAs regulate gene expression? Biochem Soc Trans 2008;36:1224-31.
3. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522-31.
4. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101:2999-3004.
5. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
6. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. Embo Mol Med 2012;4:143-59.
7. Cibas ES, Ali SZ. Conference NCITFSotS. The bethesda system for reporting thyroid cytopathology. Am J Clin Pathol 2009;132:658-65.
8. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009;94:2092-8.
9. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005;102:19075-80.
10. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008;93:1600-8.
11. Chou CK, Yang KD, Chou FF, Huang CC, Lan YW, Lee YF, et al. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. J Clin Endocrinol Metab 2013;98:E196-205.
12. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-8.
13. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE 2011;6:e17745.
14. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010;50:298-301.
15. Shen J, Liu Z, Todd NW, Zhang H, Liao J, Yu L, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 2011;11:374.
16. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010;102:1174-9.
17. Hsu CM, Lin PM, Wang YM, Chen ZJ, Lin SF, Yang MY. Circulating miRNA is a novel marker for head and neck squamous cell carcinoma. Tumour Biol 2012;33:1933-42.
18. Chan JK, Saw D. The grooved nucleus. A useful diagnostic criterion of papillary carcinoma of the thyroid. Am J Surg Pathol 1986;10:672-9.
19. Chou CK, Chen RF, Chou FF, Chang HW, Chen YJ, Lee YF, et al. MiR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid 2010;20:489-94.
20. Nikiforova MN, Chiosea SI, Nikiforov YE. MicroRNA expression profiles in thyroid tumors. Endocr Pathol 2009;20:85-91.
21. Kim SY, Jeon TY, Choi CI, Kim DH, Kim DH, Kim GH, et al. Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. J Mol Diagn 2013;15:661-9.
22. Rago T, Vitti P. Role of thyroid ultrasound in the diagnostic evaluation of thyroid nodules. Best Pract Res Clin Endocrinol Metab 2008;22:913-28.
23. Mendez W, Rodgers SE, Lew JI, Montano R, Solorzano CC. Role of surgeonperformed ultrasound in predicting malignancy in patients with indeterminate thyroid nodules. Ann Surg Oncol 2008;15:2487-92.
24. Yoshizawa JM, Wong DT. Salivary microRNAs and oral cancer detection. Methods Mol Biol 2013;936:313-24.
25. Garcia JM, Garcia V, Pena C, Dominguez G, Silva J, Diaz R, et al. Extracellular plasma RNA from colon cancer patients is confined in a vesicle-like structure and is mRNA-enriched. RNA 2008;14:1424-32.
26. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer 2012;130:1378-86.
27. Li M, Li J, Ding X, He M, Cheng SY. MicroRNA and cancer. AAPS J 2010;12:309-17.
28. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
29. Schwertheim S, Sheu SY, Worm K, Grabellus F, Schmid KW. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Horm Metab Res 2009;41:475-81.
30. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006;30:216-22.
31. Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ, Lee NS, et al. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg 2012;203:436-41.
32. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006;12:1623-9.
33. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 2006;13:497-508.
34. Vriens MR, Weng J, Suh I, Huynh N, Guerrero MA, Shen WT, et al. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer 2012;118:3426-32.
35. Agretti P, Ferrarini E, Rago T, Candelieri A, De Marco G, Dimida A, et al. MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration. Eur J Endocrinol 2012;167:393-400.
36. Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R, et al. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res 2012;18:2032-8.
37. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer 2003;98:31-40.
38. Lee YS, Lim YS, Lee JC, Wang SG, Kim IJ, Son SM, et al. Clinical implications of bilateral lateral cervical lymph node metastasis in papillary thyroid cancer: a risk factor for lung metastasis. Ann Surg Oncol 2011;18:3486-92.
39. Caminha LS, Momesso DP, Vaisman F, Corbo R, Vaisman M. Long-term followup of patients with differentiated thyroid cancer who had negative 131I whole-body scan at first evaluation after treatment. Clin Nucl Med 2013;38:765-9.
40. Ozkan E, Aras G, Kucuk NO. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results. Clin Nucl Med 2013;38:326-31.
41. Cooper DS, Doherty GM, Haugen BR, Kloos RT, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.